Verona Pharma - Adr (VRNA) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Verona Pharma - Adr in October 2026.
Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Verona Pharma - Adr (VRNA) Stock Forecast
Analyst price target, next 12 months
$60.20
-43.7% vs today's $106.91
Price range over the last 12 months
Close to its 12-month high
Analysts covering Verona Pharma - Adr have a consensus 12-month target of $60.20, below the current price of $106.91.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 16 Apr 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Verona Pharma's stock, with a target price indicating potential decline.
Financial Health
Verona Pharma is generating strong revenue and has an impressive profit margin, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.